UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported):  June 17, 2010
 
Interleukin Genetics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
 
Delaware
(State or Other Jurisdiction of Incorporation)
 
001-32715
 
94-3123681
(Commission File Number)
 
(IRS Employer Identification No.)
     
135 Beaver Street Waltham, MA
 
02452
(Address of Principal Executive Offices)
 
(Zip Code)
 
(781) 398-0700
(Registrant’s Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 5.07  Submission of Matters to a Vote of Security Holders.
 
Interleukin Genetics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 17, 2010.  Holders of 30,010,763 shares of the Company’s common stock and 5,000,000 shares of the Company’s Series A preferred stock (the “Preferred Stock”) were present in person or by proxy.  Each share of the Preferred Stock is convertible into approximately 5.63 shares of the Company’s common stock and is entitled to one vote for each share of common stock into which it is convertible.  Accordingly, shares representing 89.9 % of the aggregate voting power were present in person or by proxy at the Annual Meeting.  The following are the results of the two proposals voted on at the Annual Meeting:
 
Proposal 1 :  William C. Mills III was elected to serve as a Class I director for a three-year term expiring at the Company’s 2013 annual meeting of stockholders.  The following chart shows the number of votes cast for the election of Mr. Mills, as well as the number of votes withheld:

 
For
Withheld
Common Stock
12,777,774
212,149
Preferred Stock
5,000,000
0

In addition, there were 17,020,840 broker non-votes on Proposal 1.

Proposal 2 :  The appointment of Grant Thornton LLP as the Company’s independent public accountant for the fiscal year ending December 31, 2010 was ratified by the stockholders.  The following chart shows the number of votes cast for and against this proposal, as well as the number of votes that abstained:

 
For
Against
Abstain
Common Stock
29,919,542
63,488
27,733
Preferred Stock
5,000,000
0
0

 
2
 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
   
Interleukin Genetics, Inc.
   
(Registrant)
     
Date: June 21, 2010
 
/s/ ELIOT M. LURIER
   
 Eliot M. Lurier
   
 Chief Financial Officer
   
 (Signature)
 
 
3
 

Interleukin Genetics (AMEX:ILI)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Interleukin Genetics.
Interleukin Genetics (AMEX:ILI)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Interleukin Genetics.